ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO1312

Long-Term Efficacy of Migalastat on Renal Function and Outcomes in Patients with Fabry Disease (FD)

Session Information

Category: Genetic Diseases of the Kidneys

  • 1002 Genetic Diseases of the Kidneys: Non-Cystic

Authors

  • Bichet, Daniel G., Department of Medicine, Hôpital du Sacré-Coeur, University of Montréal, Montréal, Quebec, Canada
  • Feldt-Rasmussen, Ulla, Department of Medical Endocrinology and Metabolism, Rigshospitalet, National University Hospital, Copenhagen University, Copenhagen, Denmark
  • Giugliani, Roberto, Medical Genetics Service, HCPA, Department of Genetics, UFRGS, and INAGEMP, Porto Alegre, Brazil
  • Hughes, Derralynn, Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust and University College London, London, United Kingdom
  • Krusinska, Eva, Amicus Therapeutics, Inc., Philadelphia, Pennsylvania, United States
  • Veleva-Rotse, Biliana O., Amicus Therapeutics, Inc., Philadelphia, Pennsylvania, United States
Background

FD, caused by pathogenic GLA variants leading to functional deficiency of α-galactosidase A (α-Gal A), can eventually result in key organ damage. Preserving renal function and preventing Fabry-associated clinical events (FACEs) are important treatment goals. Approved therapies include enzyme replacement therapy (ERT) and the pharmacological chaperone migalastat. Stabilized renal function and FACE occurrence up to 30 mo have been reported in migalastat-treated adults with amenable GLA variants; here, we extend those analyses up to 8.6 yrs.

Methods

Integrated data from phase 3 clinical trials (FACETS, NCT00925301; ATTRACT, NCT01218659) and open-label extension studies (NCT01458119; NCT02194985) were used to evaluate the eGFR slope using linear regression in pts treated with migalastat for ≥2 yrs (n=78). Incidences of FACEs (predefined renal, cardiac, and cerebrovascular events) were assessed in all pts (N=97). Analyses were stratified by prior treatment and phenotype. Cox regression modeling was used to identify predictors of FACEs.

Results

eGFR remained stable for both ERT-naive and ERT-experienced pts who received migalastat for ≥2 yrs (median [min-max] duration: 5.9 [2.0-8.6]); the mean (SD) annualized rates of change in eGFR (mL/min/1.73 m2) were –1.6 (3.1) and –1.6 (3.6), respectively. In male pts with the classic phenotype (classification based on multiorgan involvement and [ERT-naive only] α-Gal A level at baseline; n=25), mean (SD) rate of change in eGFR was –2.2 (4.4) mL/min/1.73 m2. eGFR was also analyzed by baseline renal function and proteinuria levels. In all migalastat-treated pts (median duration: 5.1 yrs), the incidence of composite FACEs (per 1000 patient-years) was 48.3 (65.3 for classic males) and incidence of renal events was 4.4 (14.5 for classic males). Lower baseline eGFR was a predictor of FACEs in classic males vs all others; however, rate of renal events was too low to analyze predictors.

Conclusion

Results demonstrate long-term efficacy of migalastat in stabilizing eGFR in pts with FD, including male pts with the classic phenotype. FACE incidence in pts receiving migalastat compared favorably to historic reports of ERT. The inverse correlation of eGFR with FACEs suggests the importance of early diagnosis and treatment to preserve renal function.

Funding

  • Commercial Support –